IDEMIA Partners with ITSO to Bring Smart Mobile Ticketing in the UK
IDEMIA, the global leader in Augmented Identity, today announced that it is working with ITSO Transit Hub Ltd (ITHL) to enable the digital ticket fulfillment process within ITSO on Mobile, bringing the UK’s trusted national smartcard to mobile phones for the first time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190225005366/en/
(Graphic: Business Wire)
The technology is enabled by Google Pay, and supported by IDEMIA’s leading solutions, ensuring an instant, secure and seamless ticketing experience for passengers.
To allow passengers to fulfil and use an ITSO compatible ticket on their mobile phones, ITHL has enlisted the services of IDEMIA Digital Enablement Platform, a comprehensive card digitization solution to build and host Transit Hub. Transit Hub is a fundamental part of the solution that manages the ticket fulfilment, provisioning and reporting service for ITSO on Mobile. In doing so, ITHL and IDEMIA aim to make ticketing better and smarter for the travelling public.
ITSO Ltd offers the only nationwide, inter-operable smart ticketing solution for public transport and has for many years worked to deliver ITSO smartcard services to an ever-wider population of passengers. ITSO is already in place throughout much of the UK accounting for over 2 billion journeys per year.
2019 will see the industry embrace ITSO on Mobile smart tickets. Passengers will be able to buy tickets on the move, switch between operators and modes of transport and access real time data – all from their mobile phone. Operators will be able to roll out mobile tickets quickly and easily with minimum disruption to their current infrastructure and see the cost savings with this easy implementation.
“We are proud to be working with ITSO Transit Hub Ltd to enable a first of its kind smart mobile ticketing service. Public Transport Operators can connect their systems to the ITSO Transit Hub, a centralized and unique platform for digitizing ITSO smart tickets. The solution is based on IDEMIA’s field proven Digital Enablement Platform, deployed at scale in a dozen countries and provisioning millions of cards across all major wallets,” says Amanda Gourbault, Executive Vice-President for Financial Institutions activities at IDEMIA.
Steve Wakeland, Chief Executive Officer at ITSO Transit Hub Ltd, adds: “IDEMIA has been a key technology partner to help us deliver the ITSO smart mobile ticketing services. In this case, smart really does mean smart. Planning, paying and remote download is done securely in no time compared to some existing schemes that have their limitations and security risks. The handset becomes the ticket machine and the ticket. As the ticket is virtual, it is accepted instantly when tapped on a reader.”
The first transport operators using ITSO on Mobile’s mobile ticketing went live in November 2018 on the Swift metro tram in the West Midlands.
IDEMIA, the global leader in Augmented Identity, provides a trusted
environment enabling citizens and consumers alike to perform their daily
critical activities (such as pay, connect, travel and vote), in the
physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to $3 billion in revenues and 13,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About ITSO Transit Hub
ITSO Transit Hub develops, delivers into service and then operates ITSO on Mobile, including the fulfilment of mobile ticket purchases on behalf of ITSO Ltd.
About ITSO Ltd:
ITSO Ltd is a non-profit distributing membership organisation which aims to make travelling on public transport throughout the UK seamless and easy by enabling smart ticketing technology. The ITSO community is a membership of public sector authorities, transport operators and equipment and solution suppliers to the smart ticketing industry, who together use the ITSO Specification to deliver smart, integrated and interoperable ticketing across the UK. For more information about ITSO on Mobile visit www.itso.org.uk.
HAVAS PARIS PR agency
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science26.5.2019 10:00:00 EEST | Tiedote
Nanopharmaceutics promises ground-breaking innovation in the development of medicines: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/ The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medic
XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival25.5.2019 21:20:00 EEST | Tiedote
On May 16 (local time), an event was held at the 72nd Cannes Film Festival to recommend China’s most beautiful shooting locations on the theme of “Fascinating China.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190525005008/en/ The representative from Cannes Convention Bureau (1st L), Michel Chevillon (C), vice president of the French Riviera Chamber of Commerce and Industry and head of hotel association, and Adeline CHAUVEAU (3rd R), officer in charge of film and television projects from French Embassy to China, pose for a group photo with the representatives from the cities awarded for "The most beautiful shooting location in China." (Photo: Business Wire) In the event, the Yellow Sea National Forest Park in Dongtai, Jiangsu Province, the One Hundred Mile Azalea Forest in Bijie, Guizhou Province, Siming District of Xiamen, Fujian Province, and the Li Autonomous County in Lingshui, Hainan Province were on the list. The p
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 17:00:00 EEST | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo
Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 13:20:00 EEST | Tiedote
Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 08:00:00 EEST | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of
The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 04:00:00 EEST | Tiedote
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme